case_images: PMC7171698_01
case_images: A: Case 1, induction therapy with 6 doses of eculizumab. Serum creatinine and thrombocytes from admission to last follow-up (week 211). Breast-conserving surgery was performed 7 weeks after withdrawal of eculizumab, followed by radiation therapy 3 months later. TPE = therapeutic plasma exchange; CVVHD = continuous veno-venous hemodialysis; HD = hemodialysis. B: Case 2, induction therapy with 8 doses of eculizumab. Serum creatinine and thrombocytes from admission to last-follow up (week 42). FFP = fresh frozen plasma.
case_images: CNCS-8-025-01.jpg
case_images: PMC7171698_02_CNCS-8-025-01.jpg
case_images: Figure1
case_images: TMA occurred (Figure 1B) (Table 2). The patient died of pancreatic cancer 18 months after initial hospital admission. 
case_images: PMC7171698_02
case_images: A: Case 1, induction therapy with 6 doses of eculizumab. Serum creatinine and thrombocytes from admission to last follow-up (week 211). Breast-conserving surgery was performed 7 weeks after withdrawal of eculizumab, followed by radiation therapy 3 months later. TPE = therapeutic plasma exchange; CVVHD = continuous veno-venous hemodialysis; HD = hemodialysis. B: Case 2, induction therapy with 8 doses of eculizumab. Serum creatinine and thrombocytes from admission to last-follow up (week 42). FFP = fresh frozen plasma.
case_images: CNCS-8-025-01.jpg
case_images: PMC7171698_02_CNCS-8-025-01.jpg
case_images: Figure1
case_images: TMA occurred (Figure 1B) (Table 2). The patient died of pancreatic cancer 18 months after initial hospital admission. 